The global cancer supportive care products market is witnessing significant growth, driven by the rising prevalence of cancer worldwide and the increasing focus on improving the quality of life for cancer patients. Cancer supportive care products encompass a wide range of therapies and medications designed to manage the side effects of cancer treatment and improve patient comfort. These products include antiemetics, pain relievers, growth factors, and nutritional supplements, among others. The market is also benefiting from advancements in supportive care therapies, such as the development of targeted therapies and personalized medicine. Additionally, the growing awareness about supportive care among healthcare providers and patients is driving market expansion.
Data Bridge Market Research analyses that the Cancer Supportive Care Products Market was valued at USD 20,124.54 million in 2021 and is further estimated to reach USD 24,519.80 million by 2029, and is expected to grow at a CAGR of 2.5% during the forecast period of 2022 to 2029.
Below are the Top Five Cancer Supportive Care Products Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Amgen Inc.
|
Amgen Inc. is a prominent player in the global cancer supportive care products market, known for its innovative therapies and medications aimed at improving the quality of life for cancer patients. The company offers a range of supportive care products, including antiemetics, pain management drugs, and bone health medications, among others. Amgen's commitment to research and development has led to the development of novel therapies that target the side effects of cancer treatment, such as chemotherapy-induced nausea and vomiting, anemia, and bone complications.
|
|
North America
|
In January 2020, Amgen Inc. announced the successful strategic collaboration with BeiGene. It is predicted that this collaboration anticipated enhancing the company’s footprints in China Oncology market in the coming years.
|
|
2.
|
Pfizer Inc.
|
Pfizer Inc. is a key player in the global cancer supportive care products market, offering a diverse range of therapies and medications aimed at improving the quality of life for cancer patients. The company's portfolio includes antiemetics, pain management drugs, and supportive care medications that address the side effects of cancer treatment such as chemotherapy-induced nausea and vomiting, anemia, and fatigue.
|
|
North America, Middle East and Africa, Europe, Latin America, Asia- Pacific
|
In September 2021, Pfizer Inc. announced the strategic collaboration with essential Flatiron Health. The primary purpose of strategic collaboration is to incorporate and upsurge the usage of real-world data in development of innovative targeted cancer medicines. Consequently, it is expected to escalate the product portfolio of the company.
|
|
3.
|
Janssen Global Services, LLC,
|
Janssen Global Services, LLC, a subsidiary of Johnson & Johnson, is a significant player in the global cancer supportive care products market. Janssen offers a range of supportive care products designed to improve the quality of life for cancer patients. These products include antiemetics, pain management drugs, and medications to manage other treatment-related side effects such as anemia and neutropenia.
|
|
North America
|
In December 2019, Janssen Global Services, LLC announced the acquisition with TARIS Biomedical LLC (TARIS) which is a privately-owned biotechnology company. The purpose behind the acquisition is to develop of a novel drug delivery technology for the treatment of bladder diseases including cancer.
|
|
4.
|
Novartis AG
|
Novartis AG is a key player in the global cancer supportive care products market, offering a wide range of therapies and medications aimed at improving the quality of life for cancer patients. The company's portfolio includes antiemetics, pain management drugs, and supportive care medications that address the side effects of cancer treatment such as chemotherapy-induced nausea and vomiting, anemia, and fatigue.
|
|
Middle East, Europe, America, Asia- Pacific
|
In September 2020, Novartis AG announced the result of Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab in combination with the targeted therapies Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar and Mekinist combination. The result was announced during the European Society of Medical Oncology (ESMO) Virtual Congress 2020. It is expected that this announcement may enhance the company footprints in Europe market.
|
Conclusion
The global cancer supportive care products market is witnessing significant growth, driven by the rising prevalence of cancer worldwide and the increasing focus on improving the quality of life for cancer patients. Companies such as Amgen Inc., Pfizer Inc., Janssen Global Services, LLC, and Novartis AG are playing a crucial role in this market, offering innovative therapies and medications to address the side effects of cancer treatment. These companies' strong market presence, diverse product portfolios, and commitment to research and development have positioned them as key players in the global market. With the increasing demand for supportive care products and ongoing advancements in treatment options, the future looks promising for the global cancer supportive care products market.
